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SUMMARY  13 
Height is a highly heritable, classic polygenic trait with ~700 common associated variants 14 
identified so far through genome-wide association studies. Here, we report 83 height-associated 15 
coding variants with lower minor allele frequencies (range of 0.1-4.8%) and effects of up to 2 16 
cm/allele (e.g. in IHH, STC2, AR and CRISPLD2), >10 times the average effect of common 17 
variants. In functional follow-up studies, rare height-increasing alleles of STC2 (+1-2 cm/allele) 18 
compromised proteolytic inhibition of PAPP-A and increased cleavage of IGFBP-4 in vitro, 19 
resulting in higher bioavailability of insulin-like growth factors. These 83 height-associated 20 
variants overlap genes mutated in monogenic growth disorders and highlight new biological 21 
candidates (e.g. ADAMTS3, IL11RA, NOX4) and pathways (e.g. 22 
proteoglycan/glycosaminoglycan synthesis) involved in growth. Our results demonstrate that 23 
sufficiently large sample sizes can uncover rare and low-frequency variants of moderate to large 24 
effect associated with polygenic human phenotypes, and that these variants implicate relevant 25 
genes and pathways.  26 
 27 
  28 
 3 
INTRODUCTION 29 
Human height is a highly heritable, polygenic trait
1,2
. The contribution of common DNA 30 
sequence variation to inter-individual differences in adult height has been systematically 31 
evaluated through genome-wide association studies (GWAS). This approach has thus far 32 
identified 697 independent variants located within 423 loci that together explain ~20% of the 33 
heritability of height
3
. As is typical of complex traits and diseases, most of the height alleles 34 
discovered so far are common (minor allele frequency (MAF) >5%) and are mainly located 35 
outside coding regions, complicating the identification of the relevant genes or functional 36 
variants. Identifying coding variants associated with a complex trait in new or known loci has the 37 
potential to pinpoint causal genes. Furthermore, the extent to which rare (MAF <1%) and low-38 
frequency (1%< MAF ≤ 5%) coding variants also influence complex traits and diseases remains 39 
an open question. Many recent DNA sequencing studies have identified only few such variants
4-40 
8
, but this limited success could be due to their modest sample size
9
. Some studies have 41 
suggested that common sequence variants may explain the majority of the heritable variation in 42 
adult height
10
, making it timely to assess whether and to what extent rare and low-frequency 43 
coding variation contributes to the genetic landscape of this model polygenic trait.  44 
 45 
In this study, we used an ExomeChip
11
 to test the association between 241,453 variants (83% 46 
coding with MAF ≤5%) and adult height variation in 711,428 individuals (discovery and 47 
validation sample sizes were 458,927 and 252,501, respectively). The ExomeChip is a 48 
genotyping array designed to query in very large sample sizes coding variants identified by 49 
whole-exome DNA sequencing of ~12,000 participants. The main goals of our project were to 50 
determine whether rare and low-frequency coding variants influence the architecture of a model 51 
 4 
complex human trait, such as adult height, and to discover and characterize new genes and 52 
biological pathways implicated in human growth. 53 
  54 
 5 
RESULTS 55 
32 rare and 51 low-frequency coding variants associated with adult height 56 
We conducted single-variant meta-analyses in a discovery sample of 458,927 individuals, of 57 
whom 381,625 were of European ancestry. We validated our association results in an 58 
independent set of 252,501 participants. We first performed standard single-variant association 59 
analyses; technical details of the discovery and validation steps are in Methods (Extended Data 60 
Figs 1-3, Supplementary Tables 1-11). In total, we found 606 independent ExomeChip variants 61 
at array-wide significance (P<2x10
-7
), including 252 non-synonymous or splice site variants 62 
(Methods and Supplementary Table 11). Focusing on non-synonymous or splice site variants 63 
with MAF <5%, our single-variant analyses identified 32 rare and 51 low-frequency height-64 
associated variants (Extended Data Tables 1-2). To date, these 83 height variants (MAF range 65 
0.1-4.8%) represent the largest set of validated rare and low-frequency coding variants associated 66 
with any complex human trait or disease. Among these 83 variants, there are 81 missense, one 67 
nonsense (in CCND3), and one essential acceptor splice site (in ARMC5) variants.  68 
 69 
We observed a strong inverse relationship between MAF and effect size (Fig. 1). Although 70 
power limits our capacity to find rare variants of small effects, we know that common variants 71 
with effect sizes comparable to the largest seen in our study would have been easily discovered 72 
by prior GWAS, but were not detected. Our results agree with a model based on accumulating 73 
theoretical and empirical evidences that suggest that variants with strong phenotypic effects are 74 
more likely to be deleterious, and therefore rarer
12,13
. The largest effect sizes were observed for 75 
four rare missense variants, located in the androgen receptor gene AR (rs137852591, 76 
MAF=0.21%, Pcombined=2.7x10
-14
), in CRISPLD2 (rs148934412, MAF=0.08%, Pcombined=2.4x10
-77 
20
), in IHH (rs142036701, MAF=0.08%, Pcombined=1.9x10
-23
), and in STC2 (rs148833559, 78 
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MAF=0.1%, Pcombined=1.2x10
-30
). Carriers of the rare STC2 missense variant are ~2.1 cm taller 79 
than non-carriers, whereas carriers of the remaining three variants (or hemizygous men that carry 80 
the X-linked AR-rs137852591 rare allele) are ~2 cm shorter than non-carriers. In comparison, the 81 
mean effect size of common height alleles is ten times smaller in the same dataset. Across all 83 82 
rare and low-frequency non-synonymous variants, the minor alleles were evenly distributed 83 
between height-increasing and -decreasing effects (48% vs. 52%, respectively) (Fig. 1 and 84 
Extended Data Tables 1-2).  85 
 86 
Coding variants in new and known height loci, and heritability explained 87 
Many of the height-associated variants in this ExomeChip effort are located near common 88 
variants previously associated with height. Of the 83 rare and low-frequency non-synonymous 89 
variants, two low-frequency missense variants were previously identified (in CYTL1 and 90 
IL11)
3,14
 and 47 fell within 1 Mb of a known height signal; the remaining 34 define new loci. We 91 
used conditional analysis in the UK Biobank dataset and confirmed that 38 of these 47 variants 92 
were independent from the previously described height SNPs (Supplementary Table 12). We 93 
validated the UK Biobank conditional results using an orthogonal imputation-based methodology 94 
implemented in the full discovery set (Extended Data Fig. 4 and Supplementary Table 12). In 95 
addition, we found a further 85 common variants and one low-frequency synonymous variant (in 96 
ACHE) that define novel loci (Supplementary Table 12). Thus, our study identified a total of 97 
120 new height loci (Supplementary Table 11).  98 
 99 
We used the UK Biobank dataset to estimate the contribution of the new height variants to 100 
heritability, which is h2~80% for adult height2. In combination, the 83 rare and low-frequency 101 
 7 
variants explained 1.7% of the heritability of height. The newly identified novel common 102 
variants accounted for another 2.4%, and all independent variants, known and novel together 103 
explained 27.4% of heritability. By comparison, the 697 known height SNPs explain 23.3% of 104 
height heritability in the same dataset (vs. 4.1% by the new height variants identified in this 105 
ExomeChip study). We observed a modest positive association between MAF and heritability 106 
explained per variant (P=0.012, Extended Data Fig. 5), with each common variant explaining 107 
slightly more heritability than rare or low-frequency variants (0.036% vs. 0.026%, Extended 108 
Data Fig. 5). 109 
 110 
Gene-based association results 111 
To increase power to find rare or low-frequency coding variants associated with height, we 112 
performed gene-based analyses (Methods and Supplementary Tables 13-15). After accounting 113 
for gene-based signals explained by a single variant driving the association statistics, we 114 
identified ten genes with P<5x10
-7
 that harbor more than one coding variant independently 115 
associated with height variation (Supplementary Tables 16-17). These gene-based results 116 
remained significant after conditioning on genotypes at nearby common height-associated 117 
variants present on the ExomeChip (Table 1). Using the same gene-based tests in an independent 118 
dataset of 59,804 individuals genotyped on the same exome array, we replicated three genes at 119 
P<0.05 (Table 1). Further evidence for replication in these genes was seen at the level of single 120 
variants (Supplementary Table 18). From the gene-based results, three genes – CSAD, NOX4, 121 
and UGGT2 – fell outside of the loci found by single-variant analyses and are implicated in 122 
human height for the first time.  123 
 124 
Coding variants implicate biological pathways in human skeletal growth  125 
 8 
Prior pathway analyses of height loci identified by GWAS have highlighted gene sets related to 126 
both general biological processes (such as chromatin modification and regulation of embryonic 127 
size) and more skeletal growth-specific pathways (chondrocyte biology, extracellular matrix 128 
(ECM), and skeletal development)
3
. We used two different methods, DEPICT
15
 and PASCAL
16
 129 
(Methods), to perform pathway analyses using the ExomeChip results to test whether coding 130 
variants could either independently confirm the relevance of these previously highlighted 131 
pathways (and further implicate specific genes in these pathways), or identify new pathways. To 132 
compare the pathways emerging from coding and non-coding variation, we applied DEPICT 133 
separately on (1) exome array-wide associated coding variants independent of known GWAS 134 
signals and (2) non-coding GWAS loci, excluding all novel height-associated genes implicated 135 
by coding variants. We identified a total of 496 and 1,623 enriched gene sets, respectively, at a 136 
false discovery rate (FDR) <1% (Supplementary Tables 19-20); similar analyses with PASCAL 137 
yielded 362 and 278 enriched gene sets (Supplementary Tables 21-22). Comparison of the 138 
results revealed a high degree of shared biology for coding and non-coding variants (for 139 
DEPICT, gene set P-values compared between coding and non-coding results had Pearson's r = 140 
0.583, P<2.2x10
-16
; for PASCAL, Pearson's r=0.605, P<2.2x10
-16
).  However, some pathways 141 
showed stronger enrichment with either coding or non-coding genetic variation. In general, 142 
coding variants more strongly implicated pathways specific to skeletal growth (such as ECM and 143 
bone growth), while GWAS signals highlighted more global biological processes (such as 144 
transcription factor binding and embryonic size/lethality)(Extended Data Fig. 6). The two 145 
significant gene sets identified by DEPICT and PASCAL that uniquely implicated coding 146 
variants were “BCAN protein protein interaction subnetwork” and “proteoglycan binding.” Both 147 
of these pathways relate to the biology of proteoglycans, which are proteins (such as aggrecan) 148 
 9 
that contain glycosaminoglycans (such as chrondroitin sulfate) and that have well-established 149 
connections to skeletal growth
17
.  150 
 151 
We also examined which height-associated genes identified by ExomeChip analyses were 152 
driving enrichment of pathways such as proteoglycan binding. Using unsupervised clustering 153 
analysis, we observed that a cluster of 15 height-associated genes is strongly implicated in a 154 
group of correlated pathways that include biology related to proteoglycans/glycosaminoglycans 155 
(Fig. 2 and Extended Data Fig. 7). Seven of these 15 genes overlap a previously curated list of 156 
277 genes annotated in OMIM as causing skeletal growth disorders
18
; genes in this small cluster 157 
are enriched for OMIM annotations relative to genes outside the cluster (odds ratio=27.6, 158 
Fisher's exact P=1.1x10
-5
). As such, the remaining genes in this cluster may be strong candidates 159 
for harboring variants that cause Mendelian growth disorders. Within this group are genes that 160 
are largely uncharacterized (SUSD5), have relevant biochemical functions (GLT8D2, a 161 
glycosyltransferase studied mostly in the context of the liver
19
; LOXL4, a lysyl oxidase expressed 162 
in cartilage
20
), modulate pathways known to affect skeletal growth (FIBIN, SFRP4)
21,22
 or lead to 163 
increased body length when knocked out in mice (SFRP4)
23
.  164 
 165 
Functional characterization of rare STC2 variants 166 
To begin exploring whether the identified rare coding variants affect protein function, we 167 
performed in vitro functional analyses of two rare coding variants in a particularly compelling 168 
and novel candidate gene, STC2. Over-expression of STC2 diminishes growth in mice by 169 
covalent binding and inhibition of the proteinase PAPP-A, which specifically cleaves IGF 170 
binding protein-4 (IGFBP-4), leading to reduced levels of bioactive insulin-like growth factors 171 
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(Fig. 3A)
24
. Although there was no prior genetic evidence implicating STC2 variation in human 172 
growth, the PAPPA and IGFBP4 genes were both implicated in height GWAS
3
, and rare 173 
mutations in PAPPA2 cause severe short stature
25
, emphasizing the likely relevance of this 174 
pathway in humans. The two STC2 height-associated variants are rs148833559 (p.Arg44Leu, 175 
MAF=0.096%, Pdiscovery=5.7x10
-15
) and rs146441603 (p.Met86Ile, MAF=0.14%, 176 
Pdiscovery=2.1x10
-5
). These rare alleles increase height by 1.9 and 0.9 cm, respectively, suggesting 177 
that they both partially impair STC2 activity. In functional studies, STC2 with these amino acid 178 
substitutions were expressed at similar levels to wild-type, but showed clear, partial defects in 179 
binding to PAPP-A and in inhibition of PAPP-A-mediated cleavage of IGFBP-4 (Fig. 3B-D). 180 
Thus, the genetic analysis successfully identified rare coding alleles that have demonstrable and 181 
predicted functional consequences, strongly confirming the role of these variants and the STC2 182 
gene in human growth.     183 
 184 
Pleiotropic effects  185 
Previous GWAS studies have reported pleiotropic or secondary effects on other phenotypes for 186 
many common variants associated with adult height
3,26
. Using association results from 17 human 187 
complex phenotypes for which well-powered meta-analysis results were available, we explored 188 
if rare and low-frequency height variants are also pleiotropic. We found one rare and five low-189 
frequency missense variants associated with at least one of the other investigated traits at array-190 
wide significance (P<2x10
-7
) (Extended Data Fig. 8 and Supplementary Table 23). The minor 191 
alleles at rs77542162 (ABCA6, MAF=1.7%) and rs28929474 (SERPINA1, MAF=1.8%) were 192 
associated with increased height and increased levels of LDL-cholesterol (LDL-C) and total 193 
cholesterol (TC), whereas the minor allele at rs3208856 in CBLC (MAF=3.4%) was associated 194 
with increased height, HDL-cholesterol (HDL-C) and triglyceride (TG), but lower LDL-C and 195 
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TC levels. The minor allele at rs141845046 (ZBTB7B, MAF=2.8%) was associated with both 196 
increased height and body mass index (BMI). The minor alleles at the other two missense 197 
variants associated with shorter stature, rs201226914 in PIEZO1 (MAF=0.2%) and rs35658696 198 
in PAM (MAF=4.8%), were associated with decreased glycated haemoglobin (HbA1c) and 199 
increased type 2 diabetes (T2D) risk, respectively.  200 
  201 
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DISCUSSION 202 
We undertook an association study of nearly 200,000 coding variants in 711,428 individuals, and 203 
identified 32 rare and 51 low-frequency coding variants associated with adult height. 204 
Furthermore, gene-based testing discovered 10 genes that harbor several additional rare/low-205 
frequency variants associated with height, including three genes (CSAD, NOX4, UGGT2) in loci 206 
not previously implicated in height. Given the design of the ExomeChip, which did not consider 207 
variants with MAF <0.004% (or one allele in ~12,000 participants), our gene-based association 208 
results do not rule out the possibility that additional genes with such rarer coding variants also 209 
contribute to height variation; deep DNA sequencing in very large sample sizes will be required 210 
to address this question. In total, our results highlight 89 genes (10 from gene-based testing and 211 
79 from single-variant analyses (four genes have 2 independent coding variants)) that are likely 212 
to modulate human growth, and 24 alleles segregating in the general population that affect height 213 
by more than 1 cm (Extended Data Tables 1-2 and Table 1). The rare and low-frequency 214 
coding variants explain 1.7% of the heritable variation in adult height. When considering all rare, 215 
low-frequency, and common height-associated variants validated in this study, we can now 216 
explain 27.4% of the heritability.  217 
 218 
Our analyses revealed many coding variants in genes mutated in monogenic skeletal growth 219 
disorders, confirming the presence of allelic series (from familial penetrant mutations to mild 220 
effect common variants) in the same genes for related growth phenotypes in humans. We used 221 
gene set enrichment-type analyses to demonstrate the functional connectivity between the genes 222 
that harbor coding height variants, highlighting known as well as novel biological pathways that 223 
regulate height in humans (Fig. 2, Extended Data Fig. 7 and Supplementary Tables 19-22), 224 
and newly implicating genes such as SUSD5, GLT8D2, LOXL4, FIBIN, and SFRP4 that have not 225 
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been previously connected with skeletal growth. Additional interesting height candidate genes 226 
include NOX4, ADAMTS3 and ADAMTS6, PTH1R, and IL11RA (Extended Data Tables 1-2, 227 
Supplementary Tables 17 and 24). NOX4, identified through gene-based testing, encodes 228 
NADPH oxidase 4, an enzyme that produces reactive oxygen species, a biological pathway not 229 
previously implicated in human growth. Nox4
-/-
 mice display higher bone density and reduced 230 
numbers of osteoclasts, a cell type essential for bone repair, maintenance, and remodelling
12
. We 231 
also found rare coding variants in ADAMTS3 and ADAMTS6, genes that encode 232 
metalloproteinases that belong to the same family than several other human growth syndromic 233 
genes (e.g. ADAMTS2, ADAMTS10, ADAMTSL2). Moreover, we discovered a rare missense 234 
variant in PTH1R that encodes a receptor of the parathyroid hormone (PTH): PTH-PTH1R 235 
signaling is important for bone resorption and mutations in PTH1R cause chondrodysplasia in 236 
humans
27
. Finally, we replicated the association between a low-frequency missense variant in the 237 
cytokine gene IL11, but also found a new low-frequency missense variant in its receptor gene 238 
IL11RA. The IL11-IL11RA axis has been shown to play an important role in bone formation in 239 
the mouse
28,29
. Thus, our data confirm the relevance of this signaling cascade in human growth 240 
as well.  241 
 242 
Overall, our findings provide strong evidence that rare and low-frequency coding variants 243 
contribute to the genetic architecture of height, a model complex human trait. This conclusion 244 
has strong implications for the prediction of complex human phenotypes in the context of 245 
precision medicine initiatives. However, it also seems to contrast sharply with results from the 246 
recent large-scale T2D association study, which found only six variants with MAF <5% (ref. 
30
). 247 
This apparent difference could simply be explained by the large difference in sample sizes 248 
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between the two studies (711,428 for height vs. 127,145 for T2D). When we consider the 249 
fraction of associated variants with MAF<5% among all confirmed variants for height and T2D, 250 
we find that it is similar (9.7% for height vs. 7.1% for T2D). This supports the strong probability 251 
that rarer T2D alleles and more generally, rarer alleles for other polygenic diseases and traits, 252 
will be uncovered as sample sizes continue to increase.   253 
 15 
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Figure legends 422 
Figure 1. Variants with a larger effect size on height variation tend to be rarer. We observed an 423 
inverse relationship between the effect size (from the combined “discovery+validation” analysis, 424 
in cm on the y-axis) and the minor allele frequency (MAF) for the height variants (x-axis, from 0 425 
to 50%). We included in this figure the 606 height variants with P<2x10
-7
. 426 
 427 
Figure 2. Heat map showing subset of DEPICT gene set enrichment results. The full heat map is 428 
available as Extended Data Fig. 7. For any given square, the color indicates how strongly the 429 
corresponding gene (shown on the x-axis) is predicted to belong to the reconstituted gene set (y-430 
axis). This value is based on the gene’s Z-score for gene set inclusion in DEPICT’s reconstituted 431 
gene sets, where red indicates a higher Z-score and blue indicates a lower one. The proteoglycan 432 
binding pathway (bold) was uniquely implicated by coding variants by DEPICT and PASCAL. 433 
To visually reduce redundancy and increase clarity, we chose one representative "meta-gene set" 434 
for each group of highly correlated gene sets based on affinity propagation clustering 435 
(Supplementary Information). Heat map intensity and DEPICT P-values correspond to the 436 
most significantly enriched gene set within the meta-gene set; meta-gene sets are listed with their 437 
database source. Annotations for the genes indicate whether the gene has OMIM annotation as 438 
underlying a disorder of skeletal growth (black and grey) and the minor allele frequency of the 439 
significant ExomeChip (EC) variant (shades of blue; if multiple variants, the lowest-frequency 440 
variant was kept). Annotations for the gene sets indicate if the gene set was also found 441 
significant for EC by PASCAL (yellow and grey) and if the gene set was found significant by 442 
DEPICT for EC only or for both EC and GWAS (purple and green). Abbreviations: GO: Gene 443 
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Ontology; MP: mouse phenotype in the Mouse Genetics Initiative; PPI: protein-protein 444 
interaction in the InWeb database. 445 
 446 
Figure 3. STC2 mutants p.Arg44Leu (R44L) and p.Met86Ile (M86I) show compromised 447 
proteolytic inhibition of PAPP-A. (A) Schematic representation of the role of STC2 in IGF-1 448 
signaling. Partial inactivation of STC2 by height-associated DNA sequence variation could 449 
increase bioactive IGF-1 through reduced inhibition of PAPP-A. (B) Western blot analysis of 450 
recombinant STC2 wild-type and variants R44L and M86I. (C) Covalent complex formation 451 
between PAPP-A and STC2 wild-type or variants R44L and M86I. Separately synthesized 452 
proteins were analyzed by PAPP-A Western blotting following incubation for 8 h. In the absence 453 
of STC2 (Mock lane), PAPP-A appears as a single 400 kDa band (*). Following incubation with 454 
wild-type STC2, the majority of PAPP-A is present as the approximately 500 kDa covalent 455 
PAPP-A:STC2 complex (#), in which PAPP-A is devoid of proteolytic activity towards IGFBP-456 
4. Under similar conditions, incubation with variants R44L or M86I appeared to cause less 457 
covalent complex formation with PAPP-A. The gels are representative of at least three 458 
independent experiments. (D) PAPP-A proteolytic cleavage of IGFBP-4 following incubation 459 
with wild-type STC2 or variants for 1-24 h. Wild-type STC2 causes reduction in PAPP-A 460 
activity, with complete inhibition of activity following 24 h incubation. Both STC2 variants 461 
show increased IGFBP-4 cleavage (i.e. less inhibition) for all time points analyzed. Mean and 462 
standard deviations of three independent experiments are shown. One-way repeated measures 463 
analysis of variance followed by Dunnett’s post-test showed significant differences between 464 
STC2 wild-type and variants R44L (P<0.001) and M86I (P<0.01). 465 
 466 
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Extended Data Figure 1. Flowchart of the GIANT ExomeChip height study design. 467 
 468 
Extended Data Figure 2. Height ExomeChip association results. (A) Quantile-quantile plot of 469 
ExomeChip variants and their association to adult height under an additive genetic model in 470 
individuals of European ancestry. We stratified results based on allele frequency. (B) Manhattan 471 
plot of all ExomeChip variants and their association to adult height under an additive genetic 472 
model in individuals of European ancestry with a focus on the 553 independent SNPs, of which 473 
469 have MAF>5% (grey), 55 have MAF between 1 and 5% (green), and 29 have MAF<1% 474 
(blue). (C) Linkage disequilibrium (LD) score regression analysis for the height association 475 
results in European-ancestry studies. In the plot, each point represents an LD Score quantile, 476 
where the x-axis of the point is the mean LD Score of variants in that quantile and the y-axis is 477 
the mean χ2 statistic of variants in that quantile. The LD Score regression slope of the black line 478 
is calculated based on Equation 1 in Bulik-Sullivan et al.
31
 which is estimated upwards due to the 479 
small number of common variants (N=15,848) and the design of the ExomeChip. The LD score 480 
regression intercept is 1.4, the λGC is 2.7, the mean χ
2 
is 7.0, and the ratio statistic of (intercept -1) 481 
/ (mean χ2 -1) is 0.067 (standard error=0.012). (D) Scatter plot comparison of the effect sizes for 482 
all variants that reached significance in the European-ancestry discovery results (N=381,625) and 483 
results including only studies with sample sizes >5000 individuals (N=241,453). 484 
 485 
Extended Data Figure 3. Height ExomeChip association results in African-ancestry 486 
populations. Among the all-ancestry results, we found eight variants for which the genetic 487 
association with height is mostly driven by individuals of African ancestry. The minor allele 488 
frequency of these variants is <1% (or monomorphic) in all ancestries except African-ancestry 489 
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individuals. In individuals of African ancestry, the variants had allele frequencies between 9 and 490 
40%. 491 
 492 
Extended Data Figure 4. Concordance between direct conditional effect sizes using UK 493 
Biobank (x-axis) and conditional analysis performed using a combination of imputation-based 494 
methodology and approximate conditional analysis (SSimp, y-axis). The Pearson’s correlation 495 
coefficient is r=0.85. The dashed line indicates the identity line. The 95% confidence interval is 496 
indicated in both directions. Red, SNPs with Pcond>0.05 in the UK Biobank; Green, SNPs with 497 
Pcond≤0.05 in the UK Biobank. 498 
 499 
Extended Data Figure 5. Heritability estimated for all known height variants in the first release 500 
of the UK Biobank dataset. (A) We observed a weak but significant positive trend between 501 
minor allele frequency (MAF) and heritability explained (P=0.012). (B) Average heritability 502 
explained per variant when stratifying the analyses by allele frequency or genomic annotation. 503 
For heritability estimations in UKBB, variants were pruned to r
2
 < 0.2 in the 1000 Genomes 504 
Project data set, and the heritability figures are based on h
2
=80% for height. 505 
 506 
Extended Data Figure 6. Comparison of DEPICT gene set enrichment results based on coding 507 
variation from ExomeChip (EC) or non-coding variation from genome-wide association study 508 
data (GWAS). The x-axis indicates the P-value for enrichment of a given gene set using DEPICT 509 
adapted for EC data, where the input to DEPICT is the genes implicated by coding EC variants 510 
that are independent of known GWAS signals. The y-axis indicates the P-value for gene set 511 
enrichment using DEPICT, using as input the GWAS loci that do not overlap the coding 512 
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signals. Each point represents a meta-gene set, and the best P-value for any gene set within the 513 
meta-gene set is shown. Only significant (false discovery rate < 0.01) gene set enrichment results 514 
are plotted. Colors correspond to whether the meta-gene set was significant for EC only (blue), 515 
GWAS only (green), both but more significant for EC (purple), or both but more significant for 516 
GWAS (orange), and the most significant gene sets within each category are labeled.  A line is 517 
drawn at x = y for ease of comparison. 518 
 519 
Extended Data Figure 7. Heat map showing entire DEPICT gene set enrichment results 520 
(analogous to Fig. 2 in the main text). For any given square, the color indicates how strongly the 521 
corresponding gene (shown on the x-axis) is predicted to belong to the reconstituted gene set (y-522 
axis). This value is based on the gene’s Z-score for gene set inclusion in DEPICT’s reconstituted 523 
gene sets, where red indicates a higher Z-score and blue indicates a lower one.  The proteoglycan 524 
binding pathway was uniquely implicated by coding variants (as opposed to common variants) 525 
by both DEPICT and the Pascal method. To visually reduce redundancy and increase clarity, we 526 
chose one representative "meta-gene set" for each group of highly correlated gene sets based on 527 
affinity propagation clustering (see Methods and Supplementary Information).  Heat map 528 
intensity and DEPICT p-values correspond to the most significantly enriched gene set within the 529 
meta-gene set; meta-gene sets are listed with their database source. Annotations for the genes 530 
indicate whether the gene has OMIM annotation as underlying a disorder of skeletal growth 531 
(black and grey) and the minor allele frequency of the significant EC variant (shades of blue; if 532 
multiple variants, the lowest-frequency variant was kept).  Annotations for the gene sets indicate 533 
if the gene set was also found significant for EC by the Pascal method (yellow and grey) and if 534 
the gene set was found significant by DEPICT for EC only or for both EC and GWAS (purple 535 
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and green). Abbreviations: GO: Gene Ontology; KEGG: Kyoto encyclopedia of genes and 536 
genomes; MP: mouse phenotype in the Mouse Genetics Initiative; PPI: protein-protein 537 
interaction in the InWeb database. 538 
 539 
Extended Data Figure 8. Heatmaps showing associations of the height variants to other 540 
complex traits; –log10(P-values) are oriented with beta effect direction for the alternate allele, 541 
white are missing values, yellow are non-significant (P>0.05), green to blue shading for hits with 542 
positive beta in the other trait and P-values between 0.05 and <2x10
-7
 and, orange to red shading 543 
for hits with negative beta in the other trait and P-values between 0.05 to <2x10
-7
. Short and tall 544 
labels are given for the minor alleles. Clustering is done by the complete linkage method with 545 
Euclidean distance measure for the loci. Clusters highlight SNPs that are more significantly 546 
associated with the same set of traits. (A) Variants for which the minor allele is the height-547 
decreasing allele. (B) Variants for which the minor allele is the height-increasing allele.  548 
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METHODS 549 
Study design & participants 550 
The discovery cohort consisted of 147 studies comprising 458,927 adult individuals of the 551 
following ancestries: 1) European descent (N=381,625), 2) African (N=27,494), 3) South Asian 552 
(N=29,591), 4) East Asian (N=8,767); 5) Hispanic (N=10,776) and 6) Saudi (N=695). All 553 
participating institutions and coordinating centers approved this project, and informed consent 554 
was obtained from all subjects. Discovery meta-analysis was carried out in each ancestry group 555 
(except the Saudi) separately as well as in the All group. Validation was undertaken in 556 
individuals of European ancestry only (Supplementary Tables 1-3). Conditional analyses were 557 
undertaken only in the European descent group (106 studies, N=381,625).  558 
 559 
Phenotype 560 
Height (in centimeters) was corrected for age and the genomic principal components (derived 561 
from GWAS data, the variants with MAF >1% on ExomeChip, or ancestry informative markers 562 
available on the ExomeChip), as well as any additional study-specific covariates (e.g. recruiting 563 
center), in a linear regression model. For studies with non-related individuals, residuals were 564 
calculated separately by sex, whereas for family-based studies sex was included as a covariate in 565 
the model. Additionally, residuals for case/control studies were calculated separately. Finally, 566 
residuals were subject to inverse normal transformation. 567 
 568 
Genotype calling  569 
The majority of studies followed a standardized protocol and performed genotype calling using 570 
the designated manufacturer software, which was then followed by zCall
32
. For 10 studies 571 
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participating in the Cohorts for Heart and Aging Research in Genomic Epidemiology 572 
(CHARGE) Consortium, the raw intensity data for the samples from seven genotyping centers 573 
were assembled into a single project for joint calling
11
. Study-specific quality control (QC) 574 
measures of the genotyped variants was implemented before association analysis 575 
(Supplementary Tables 1-2).  576 
 577 
Study-level statistical analyses 578 
Individual cohorts were analyzed separately for each ancestry population, with either 579 
RAREMETALWORKER (http://genome.sph.umich.edu/wiki/RAREMETALWORKER) or 580 
RVTEST (http://zhanxw.github.io/rvtests/), to associate inverse normal transformed height data 581 
with genotype data taking potential cryptic relatedness (kinship matrix) into account in a linear 582 
mixed model. These software are designed to perform score-statistics based rare-variant 583 
association analysis, can accommodate both unrelated and related individuals, and provide 584 
single-variant results and variance-covariance matrix. The covariance matrix captures linkage 585 
disequilibrium (LD) relationships between markers within 1 Mb, which is used for gene-level 586 
meta-analyses and conditional analyses
33
. Single-variant analyses were performed for both 587 
additive and recessive models.  588 
 589 
Centralized quality-control 590 
The individual study data were investigated for potential existence of ancestry population 591 
outliers based on 1000 Genome Project phase 1 ancestry reference populations. A centralized QC 592 
procedure implemented in EasyQC
34
 was applied to individual study association summary 593 
statistics to identify outlying studies: (1) assessment of possible problems in height 594 
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transformation, (2) comparison of allele frequency alignment against 1000 Genomes Project 595 
phase 1 reference data to pinpoint any potential strand issues, and (3) examination of quantile-596 
quantile (QQ) plots per study to identify any problems arising from population stratification, 597 
cryptic relatedness and genotype biases. We excluded variants if they had call rate <95%, Hardy-598 
Weinberg equilibrium P<1x10
-7
, or large allele frequency deviations from reference populations 599 
(>0.6 for all ancestry analyses and >0.3 for ancestry-specific population analyses). We also 600 
excluded from downstream analyses markers not present on the Illumina ExomeChip array 1.0, 601 
variants on the Y-chromosome or the mitochondrial genome, indels, multiallelic variants, and 602 
problematic variants based on the Blat-based sequence alignment analyses. Meta-analyses were 603 
carried out in parallel by two different analysts at two sites. 604 
 605 
Single-variant meta-analyses 606 
Discovery analyses. We conducted single-variant meta-analyses in a discovery sample of 607 
458,927 individuals of different ancestries using both additive and recessive genetic models 608 
(Extended Data Fig. 1 and Supplementary Tables 1-4). Significance for single-variant 609 
analyses was defined at array-wide level (P<2x10
-7
, Bonferroni correction for 250,000 variants).  610 
The combined additive analyses identified 1,455 unique variants that reached array-wide 611 
significance (P<2x10
-7
), including 578 non-synonymous and splice site variants 612 
(Supplementary Tables 5-7). Under the additive model, we observed a high genomic inflation 613 
of the test statistics (e.g. λGC of 2.7 in European-ancestry studies for common markers, Extended 614 
Data Fig. 2 and Supplementary Table 8), although validation results (see below) and additional 615 
sensitivity analyses (see below) suggested that it is consistent with polygenic inheritance as 616 
opposed to population stratification, cryptic relatedness, or technical artifacts (Extended Data 617 
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Fig. 2). The majority of these 1,455 association signals (1,241; 85.3%) were found in the 618 
European-ancestry meta-analysis (85.5% of the discovery sample size) (Extended Data Fig. 2). 619 
Nevertheless, we discovered eight associations within five loci in our all-ancestry analyses that 620 
are driven by African studies (including one missense variant in the growth hormone gene GH1 621 
(rs151263636), Extended Data Fig. 3), three height variants found only in African studies, and 622 
one rare missense marker associated with height in South Asians only (Supplementary Table 623 
7). 624 
 625 
Genomic inflation and confounding. We observed a marked genomic inflation of the test 626 
statistics even after adequate control for population stratification (linear mixed model) arising 627 
mainly from common markers; λGC in European-ancestry was 1.2 and 2.7 for all and common 628 
markers, respectively (Extended Data Fig. 2 and Supplementary Table 8). Such inflation is 629 
expected for a highly polygenic trait like height, and is consistent with our very large sample 630 
size
3,35
. To confirm this, we applied the recently developed linkage disequilibrium (LD) score 631 
regression method to our height ExomeChip results
31
, with the caveats that the method was 632 
developed (and tested) with >200,000 common markers available. We restricted our analyses to 633 
15,848 common variants (MAF ≥5%) from the European-ancestry meta-analysis, and matched 634 
them to pre-computed LD scores for the European reference dataset
31
. The intercept of the 635 
regression of the χ2 statistics from the height meta-analysis on the LD score estimate the inflation 636 
in the mean χ2 due to confounding bias, such as cryptic relatedness or population stratification. 637 
The intercept was 1.4 (standard error = 0.07), which is small when compared to the λGC of 2.7. 638 
Furthermore, we also confirmed that the LD score regression intercept is estimated upward 639 
because of the small number of variants on the ExomeChip and the selection criteria for these 640 
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variants (i.e. known GWAS hits). The ratio statistic of (intercept -1) / (mean χ2 -1) is 0.067 641 
(standard error = 0.012), well within the normal range
31
, suggesting that most of the inflation 642 
(~93%) observed in the height association statistics is due to polygenic effects (Extended Data 643 
Fig. 2). 644 
 645 
Furthermore, to exclude the possibility that some of the observed associations between height 646 
and rare/low-frequency variants could be due to allele calling problems in the smaller studies, we 647 
performed a sensitivity meta-analysis with primarily Europe-ancestry studies totaling >5,000 648 
participants. We found very concordant effect sizes, suggesting that smaller studies do not bias 649 
our results (Extended Data Fig. 2).  650 
 651 
Conditional analyses. The RAREMETAL R-package
36
 and the GCTA v1.24
37
 software were 652 
used to identify independent height association signals across the European descent meta-653 
analysis results. RAREMETAL performs conditional analyses by using covariance matrices in 654 
order to distinguish true signals from those driven by LD at adjacent known variants. First, we 655 
identified the lead variants (P<2x10
-7
) based on a 1 Mb window centered on the most 656 
significantly associated variant and performed LD pruning (r
2
<0.3) to avoid downstream 657 
problems in the conditional analyses due to co-linearity. We then conditioned on the LD-pruned 658 
set of lead variants in RAREMETAL and kept new lead signals at P<2x10
-7
. The process was 659 
repeated until no additional signal emerged below the pre-specified P-value threshold. The use of 660 
a 1Mb window in RAREMETAL can obscure dependence between conditional signals in 661 
adjacent intervals in regions of extended LD. To detect such instances, we performed joint 662 
analyses using GCTA with the ARIC and UK ExomeChip reference panels, both of which 663 
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comprise >10,000 individuals of European descent. With the exception of a handful of variants 664 
in a few genomic regions with extended LD (e.g. the HLA region on chromosome 6), the two 665 
software identified the same independent signals (at P<2x10
-7
). 666 
 667 
To discover new height variants, we conditioned the height variants found in our ExomeChip 668 
study on the previously published GWAS height variants
3
 using the first release of the UK 669 
Biobank imputed dataset and regression methodology implemented in BOLT-LMM
38
. Because 670 
of the difference between the sample size of our discovery set (N=458,927) and the UK Biobank  671 
(first release, N=120,084), we applied a threshold of Pconditional <0.05 to declare a height variant 672 
as independent in this analysis. We also explored an alternative approach based on approximate 673 
conditional analysis
37
. This latter method (SSimp) relies on summary statistics available from the 674 
same cohort, thus we first imputed summary statistics
39
 for exome variants, using summary 675 
statistics from the Wood et al. 2014 study
3
. Conversely, we imputed the top variants from the 676 
Wood et al. 2014 study using the summary statistics from the ExomeChip. Subsequently, we 677 
calculated effect sizes for each exome variant conditioned on the Wood et al. 2014 top variants 678 
in two ways. First, we conditioned the imputed summary statistics of the exome variant on the 679 
summary statistics of the Wood et al. 2014 top variants that fell within 5 Mb of the target 680 
ExomeChip variant. Second, we conditioned the summary statistics of the ExomeChip variant on 681 
the imputed summary statistics of the Wood et al. 2014 hits. We then selected the option that 682 
yielded a higher imputation quality. For poorly tagged variants (   < 0.8), we simply used up-683 
sampled HapMap summary statistics for the approximate conditional analysis. Pairwise SNP-by-684 
SNP correlations were estimated from the UK10K data (TwinsUK
40
 and ALSPAC
41
 studies , 685 
N=3,781). 686 
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 687 
Validation of the single-variant discovery results. Several studies, totaling 252,501 independent 688 
individuals of European ancestry, became available after the completion of the discovery 689 
analyses, and were thus used for validation of our experiment. We validated the single-variant 690 
association results in eight studies, totaling 59,804 participants, genotyped on the Exomechip 691 
using RAREMETAL
33
. We sought additional evidence for association for the top signals in two 692 
independent studies in the UK (UK Biobank) and Iceland (deCODE), comprising 120,084 and 693 
72,613 individuals, respectively. We used the same QC and analytical methodology as described 694 
above. Genotyping and study descriptives are provided in Supplementary Tables 1-3. For the 695 
combined analysis, we used the inverse-variance weighted fixed effects meta-analysis method 696 
using METAL
42
. Significant associations were defined as those with a combined meta-analysis 697 
(discovery and validation) Pcombined<2x10
-7
. 698 
 699 
We considered 81 variants with suggestive association in the discovery analyses (2x10
-700 
7
<Pdiscovery≤2x10
-6
). Of those 81 variants, 55 reached significance after combining discovery and 701 
replication results based on Pcombined<2x10
-7
 (Supplementary Table 9). Furthermore, recessive 702 
modeling confirmed seven new independent markers with Pcombined<2x10
-7
 (Supplementary 703 
Table 10). One of these recessive signals is due to a rare X-linked variant in the AR gene 704 
(rs137852591, MAF=0.21%). Because of its frequency, we only tested hemizygous men (we did 705 
not identify homozygous women for the minor allele) so we cannot distinguish between a true 706 
recessive mode of inheritance or a sex-specific effect for this variant. To test the independence 707 
and integrate all height markers from the discovery and validation phase, we used conditional 708 
analyses and GCTA “joint” modeling37 in the combined discovery and validation set. This 709 
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resulted in the identification of 606 independent height variants, including 252 non-synonymous 710 
or splice site variants (Supplementary Table 11). If we only consider the initial set of lead 711 
SNPs with P <2x10
-7
, we identified 561 independent variants. Of these 561 variants (selected 712 
without the validation studies), 560 have concordant direction of effect between the discovery 713 
and validation studies, and 548 variants have a Pvalidation<0.05 (466 variants with Pvalidation 714 
<8.9x10
-5
, Bonferroni correction for 561 tests), suggesting a very low false discovery rate 715 
(Supplementary Table 11). 716 
 717 
Gene-based association meta-analyses 718 
For the gene-based analyses, we applied two different sets of criteria to select variants, based on 719 
coding variant annotation from five prediction algorithms (PolyPhen2 HumDiv and HumVar, 720 
LRT, MutationTaster and SIFT)
43
. The mask labeled “broad” included variants with a MAF 721 
<0.05 that are nonsense, stop-loss, splice site, as well as missense variants that are annotated as 722 
damaging by at least one program mentioned above. The mask labeled “strict” included only 723 
variants with MAF <0.05 that are nonsense, stop-loss, splice site, as well as missense variants 724 
annotated as damaging by all five algorithms. We used two tests for gene-based testing, namely 725 
the SKAT
44
 and VT
45
 tests. Statistical significance for gene-based tests was set at a Bonferroni-726 
corrected threshold of P<5x10
-7
 (threshold for 25,000 genes and four tests). The gene-based 727 
discovery results were validated (same test and variants, when possible) in the same eight studies 728 
genotyped on the ExomeChip (N=59,804 participants) that were used for the validation of the 729 
single-variant results (see above, and Supplementary Tables 1-3). Gene-based conditional 730 
analyses were performed in RAREMETAL. 731 
 732 
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Pleiotropy analyses 733 
We accessed ExomeChip data from GIANT (BMI, waist-hip ratio), GLGC (total cholesterol 734 
(TC), triglycerides (TG), HDL-cholesterol (HDL-C), LDL-cholesterol (LDL-C)), IBPC (systolic 735 
and diastolic blood pressure), MAGIC (glycaemic traits), REPROGEN (age at menarche and 736 
menopause), and DIAGRAM (type 2 diabetes).  For coronary artery disease, we accessed 1000 737 
Genomes Project-imputed GWAS data released by CARDIoGRAMplusC4D
46
. 738 
 739 
Pathway analyses 740 
DEPICT is a computational framework that uses probabilistically-defined reconstituted gene sets 741 
to perform gene set enrichment and gene prioritization
15
. For a description about gene set 742 
reconstitution please refer to references 
15
 and 
47
. In brief, reconstitution was performed by 743 
extending pre-defined gene sets (such as Gene Ontology terms, canonical pathways, protein-744 
protein interaction subnetworks and rodent phenotypes) with genes co-regulated with genes in 745 
these pre-defined gene set using large-scale microarray-based transcriptomics data. In order to 746 
adapt the gene set enrichment part of DEPICT for ExomeChip data, we made two principal 747 
changes. First and foremost, because DEPICT for GWAS incorporates all genes within a given 748 
LD block around each index SNP, we modified DEPICT to take as input only the gene directly 749 
impacted by the coding SNP. Second, we adapted the way DEPICT adjust for confounders (such 750 
as gene length) by generating null ExomeChip association results using Swedish ExomeChip 751 
data (Malmö Diet and Cancer (MDC), All New Diabetics in Scania (ANDIS), and Scania 752 
Diabetes Registry (SDR) cohorts, N=11,899) and randomly assigning phenotypes from a normal 753 
distribution before conducting association analysis (see Supplementary Information). For the 754 
gene set enrichment analysis of the ExomeChip data, we used significant non-synonymous 755 
 39 
variants statistically independent of known GWAS hits (and that were present in the null 756 
ExomeChip data; see Supplementary Information for details). For gene set enrichment analysis 757 
of the GWAS data, we used all loci (1) with a non-coding index SNP and (2) that did not contain 758 
any of the novel ExomeChip genes. In visualizing the analysis, we used affinity propagation 759 
clustering
48
 to group the most similar reconstituted gene sets based on their gene memberships 760 
(see Supplementary Information). Within a “meta-gene set”, the best P-value of any member 761 
gene set was used as representative for comparison. DEPICT for ExomeChip was written using 762 
the Python programming language and the code can be found at 763 
https://github.com/RebeccaFine/height-ec-depict. 764 
 765 
We also applied the PASCAL pathway analysis tool
16
 to association summary statistics for all 766 
coding variants. In brief, the method derives gene-based scores (both SUM and MAX statistics) 767 
and subsequently tests for the over-representation of high gene scores in predefined biological 768 
pathways. We used standard pathway libraries from KEGG, REACTOME and BIOCARTA, and 769 
also added dichotomized (Z-score>3) reconstituted gene sets from DEPICT
15
. To accurately 770 
estimate SNP-by-SNP correlations even for rare variants, we used the UK10K data (TwinsUK
40
 771 
and ALSPAC
41
 studies , N=3781). In order to separate the contribution of regulatory variants 772 
from the coding variants, we also applied PASCAL to association summary statistics of only 773 
regulatory variants (20 kb upstream, gene body excluded) from the Wood et al. study
3
. In this 774 
way, we could classify pathways driven principally by coding, regulatory or mixed signals. 775 
 776 
STC2 functional experiments 777 
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Mutagenesis, cell culture and transfection. For the generation of STC2 mutants (R44L and 778 
M86I), wild-type STC2 cDNA contained in pcDNA3.1/Myc-His(-) (Invitrogen)
24
 was used as a 779 
template. Mutagenesis was carried out using Quickchange (Stratagene), and all constructs were 780 
verified by sequence analysis. Recombinant wild-type STC2 and variants were expressed in 781 
human embryonic kidney (HEK) 293T cells (293tsA1609neo, ATCC CRL-3216) maintained in 782 
high-glucose DMEM supplemented 10% fetal bovine serum, 2 mM glutamine, nonessential 783 
amino acids, and gentamicin. The cells are routinely tested for mycoplasma contamination. Cells 784 
(6x10
6
) were plated onto 10 cm-dishes and transfected 18 h later by calcium phosphate 785 
coprecipitation using 10 μg plasmid DNA. Media were harvested 48 h post transfection, cleared 786 
by centrifugation, and stored at -20°C until use. Protein concentrations (58-66 nM) were 787 
determined by TRIFMA using antibodies described previously
24
. PAPP-A was expressed stably 788 
in HEK293T cells as previously reported
49
. Expressed levels of PAPP-A (27.5 nM) were 789 
determined by a commercial ELISA (AL-101, Ansh Labs, TX). 790 
 791 
STC2 and PAPP-A complex formation. Culture supernatants containing wild-type STC2 or 792 
variants were adjusted to 58 nM, added an equal volume of culture supernatant containing 793 
PAPP-A corresponding to a 2.1-fold molar excess, and incubated at 37°C. Samples were taken at 794 
1, 2, 4, 6, 8, 16, and 24 h and stored at -20
o
C. 795 
 796 
Analysis of proteolytic activity. Specific proteolytic cleavage of 
125
I-labeled IGFBP-4 is 797 
described in detail elsewhere
50
. Briefly, the PAPP-A:STC2 complex mixtures were diluted 798 
(1:190) to a concentration of 145 pM PAPP-A and mixed with preincubated 
125
I-IGFBP4 (10 799 
nM) and IGF-1 (100 nM) in 50 mM Tris-HCl, 100 mM NaCl, 1 mM CaCl2. Following 1 h 800 
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incubation at 37
o
C, reactions were terminated by the addition of SDS-PAGE sample buffer 801 
supplemented with 25 mM EDTA. Substrate and co-migrating cleavage products were separated 802 
by 12% nonreducing SDS-PAGE and visualized by autoradiography using a storage phosphor 803 
screen (GE Healthcare) and a Typhoon imaging system (GE Healthcare). Band intensities were 804 
quantified using ImageQuant TL 8.1 software (GE Healthcare). 805 
 806 
Western blotting. STC2 and covalent complexes between STC2 and PAPP-A were blotted onto 807 
PVDF membranes (Millipore) following separation by 3-8% SDS-PAGE. The membranes were 808 
blocked with 2% Tween-20, and equilibrated in 50 mM Tris-HCl, 500 mM NaCl, 0.1% Tween-809 
20, pH 9 (TST). For STC2, the membranes were incubated with goat polyclonal anti-STC2 810 
(R&D systems, AF2830) at 0.5 μg/ml in TST supplemented with 2% skim milk for 1 h at 20°C. 811 
For PAPP-A:STC2 complexes, the membranes were incubated with rabbit polyclonal anti-812 
PAPP-A
51
 at 0.63 μg/ml in TST supplemented with 2% skim milk for 16 h at 20°C. Membranes 813 
were washed with TST and subsequently incubated with polyclonal swine anti-rabbit IgG-HRP 814 
(DAKO, P0217) or polyclonal rabbit anti-goat IgG-HRP (DAKO, P0449), respectively, diluted 815 
1:2000 in TST supplemented with 2% skim milk for 1 h at 20°C. Following washing with TST, 816 
membranes were developed using enhanced chemiluminescence (ECL Prime, GE Healthcare). 817 
Images were captured using an ImageQuant LAS 4000 instrument (GE Healthcare). 818 
 819 
  820 
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Table 1. Ten height genes implicated by gene-based testing. These genes meet our three criteria for statistical significance: (1) gene-based P<5x10
-7
, 
(2) the gene does not include variants with P<2x10
-7
, and (3) the gene-based P-value is at least two orders of magnitude smaller than the P-value for 
the most significant variant within the gene. For each gene, we provide P-values for the four different gene-based tests applied. P-values in bold are 
the most significant results for a given gene. 
1
Validation (N=59,804) and combined results using the same test and (when possible) variants. 
2
When 
the gene is located in a locus identified by our single-variant analysis (1 Mb window), we conditioned the gene-based association result on genotypes 
at the single variant(s). 
3
If the gene falls within a known GWAS height locus, we mention if it was predicted to be causal using bioinformatic tools 
(ref. 
3
). NA, not applicable. 
Gene 
Discovery gene-based P-value 
Validation 
P-value
1
 
Combined 
P-value
1
 
Conditional 
P-value
2
 
Note
3
 SKAT-
broad 
VT-
broad 
SKAT-
strict 
VT-
strict 
OSGIN1 4.3x10
-11
 4.5x10
-5
 0.19 0.18 0.048 2.6x10
-12
 7.7x10
-11
 Known locus. No predicted causal genes. 
CRISPLD1 2.2x10
-7
 6.7x10
-11
 8.5x10
-6
 8.9x10
-7
 0.50 1.2x10
-12
 NA 
Known locus, sentinel GWAS SNP not tested on 
ExomeChip. CRISPLD1 was predicted to be causal. 
CSAD 2.3x10
-8
 2.4x10
-9
 0.83 0.59 0.54 2.0x10
-9
 NA New locus. 
SNED1 1.9x10
-5
 4.3x10
-9
 NA NA 0.083 4.5x10
-10
 1.4x10
-9
 Known locus. SNED1 was not predicted to be causal. 
G6PC 1.3x10
-5
 3.6x10
-8
 5.5x10
-6
 1.3x10
-6
 0.24 5.2x10
-8
 3.9x10
-8
 
Known locus, G6PC was not predicted to be causal. 
G6PC is mutated in glycogen storage disease Ia. 
NOX4 5.1x10
-6
 1.4x10
-7
 NA NA 0.013 5.5x10
-9
 NA New locus. 
UGGT2 3.0x10
-5
 2.6x10
-7
 2.3x10
-5
 4.8x10
-7
 0.64 3.4x10
-7
 NA New locus. 
FLNB 2.2x10
-6
 5.1x10
-4
 2.4x10
-9
 3.2x10
-6
 0.016 8.6x10
-11
 3.6x10
-9
 
Known locus. FLNB was predicted to be causal. 
FLNB is mutated in atelosteogenesis type I. 
B4GALNT3 2.4x10
-5
 1.9x10
-5
 1.8x10
-5
 3.1x10
-7
 0.79 4.3x10
-7
 7.7x10
-7
 Known locus. B4GALNT3 was predicted to be causal. 
CCDC3 6.3x10
-4
 6.3x10
-6
 3.0x10
-7
 5.4x10
-9
 0.080 1.2x10
-9
 1.6x10
-9
 Known locus. CCDC3 was predicted to be causal. 
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